Hinge Health, Inc. SEC Filings

Hinge Health, Inc. (HNGE) reported an insider equity transaction by its President on a Form 4. On 11/18/2025, the officer had 15,977 shares of Class A common stock withheld and cancelled at a price of $40.84 per share to cover federal and state tax obligations arising from the vesting of restricted stock units, in an exempt transaction under Section 16b-3(e). After this tax-withholding event, the officer beneficially owned 804,904 shares of Class A common stock, which include 781 shares acquired on November 14, 2025 through the company’s employee stock purchase plan.

Hinge Health, Inc. (HNGE) reported an insider equity transaction by its Chief Financial Officer on 11/18/2025. The filing shows that 34,903 shares of Class A common stock were disposed of at $40.84 per share in a transaction classified as exempt under Section 16b-3(e). These shares were withheld and cancelled to cover federal and state tax obligations arising from the vesting of restricted stock units, rather than being sold in the open market.

After this tax-withholding event, the CFO beneficially owns 525,248 shares of Class A common stock. This total includes 781 shares acquired on November 14, 2025 through the company’s employee stock purchase plan.

A stockholder of HNGE filed a Form 144 notice to sell up to 3,813 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $166,257.86. The filing reports that 37,919,155 shares of common stock were outstanding. The shares to be sold were acquired as restricted stock from the issuer on 10/01/2024 (2,188 shares) and 01/01/2025 (1,625 shares), both fully paid in stock rather than cash.

The notice also discloses that Kristina Leslie, at a listed San Francisco address, sold 2,187 shares of common stock on 11/18/2025 for gross proceeds of $88,476.40. The proposed new sale is expected around 11/19/2025 on the NYSE, and the signer represents they are not aware of undisclosed material adverse information about the issuer.

HNGE has a shareholder filing a Rule 144 notice to sell 351,045 Class A shares through Merrill Lynch on the NYSE, with an approximate sale date of 11/18/2025.

The filing lists an aggregate market value of 14,336,677.8 for the shares to be sold and notes that 37,919,155 shares were outstanding. The shares were originally acquired from the issuer in a private placement on 02/04/2020 for cash. The signer represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.

HNGE shareholder filed a Rule 144 notice to sell 373,955 Class A shares, with an aggregate market value of 15,272,322.2. These shares were originally acquired from the issuer in a private placement on 02/04/2020 and paid for in cash. The proposed sales are expected to begin around 11/18/2025 through broker Merrill Lynch on the NYSE. The notice states that 37,919,155 Class A shares are outstanding, giving context for the size of this planned sale.

HNGE insider filed a Form 144 notice to sell 2,187 shares of common stock, with an aggregate market value of $88,476.40. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 11/18/2025. These shares were acquired as restricted stock from the issuer on 07/01/2024, with full payment made that same day. The filing notes that 37,919,155 shares of this class are outstanding and includes the standard representation that the seller is not aware of any undisclosed material adverse information about HNGE’s operations, including where a Rule 10b5-1 trading plan is used.

Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh filed an amended Schedule 13G reporting their beneficial ownership of 1,293,007 shares of Hinge Health, Inc. Class A common stock, representing 4.75% of the class. They report shared power to vote and dispose of all of these shares, with no sole voting or dispositive power. The group states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Hinge Health. The ownership percentage is calculated using 37,919,155 shares of common stock outstanding as of September 30, 2025, as referenced from the company’s Form 10-Q.

Hinge Health (HNGE) announced a share repurchase authorization. The Board approved a program to buy back up to $250.0 million of Class A common stock. The company disclosed that repurchases may occur in the open market, through privately negotiated transactions, or by other methods, and may be conducted in accordance with Rule 10b-18. The company may also use Rule 10b5-1 plans.

The authorization does not obligate Hinge Health to repurchase any specific amount and can be modified, suspended, or terminated at any time at the Board’s discretion. The company expects to fund repurchases with existing cash and cash equivalents and ongoing cash from operations.

Hinge Health (HNGE) reported Q3 2025 results showing strong top-line growth with ongoing investment-driven losses. Revenue reached $154.2 million, up from $100.6 million a year ago, as more clients and members used its musculoskeletal care platform. Gross profit was $126.2 million.

Operating loss was $6.1 million and net loss was $1.8 million for the quarter. For the first nine months of 2025, revenue totaled $417.1 million versus $273.1 million a year ago, while a large increase in operating expenses, including stock-based compensation, drove a net loss of $560.4 million. The company ended the quarter with $261.3 million in cash and cash equivalents and $233.8 million in marketable securities, and generated $107.5 million of operating cash flow year-to-date. Deferred revenue rose to $299.7 million, reflecting billed but not yet recognized subscription revenue.